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ORIGINAL ARTICLE Open Access
The impact of sarcopenia and myosteatosis
on postoperative outcomes in patients with
inflammatory bowel disease
Stephen O’Brien1,2, Richard G. Kavanagh3, Brian W. Carey3* , Michael M. Maher3,4, Owen J. O’Connor3,4
and Emmet J. Andrews2
Abstract
Background: Inflammatory bowel disease (IBD) is a relatively common disorder with significant associated morbidity.
Sarcopenia and myosteatosis are associated with adverse postoperative outcomes. This study investigated outcomes in
IBD patients undergoing surgical resection relative to the presence of sarcopenia and myosteatosis.
Methods: A retrospective analysis of a prospectively maintained surgical database was conducted. All patients
undergoing elective or emergency resection for IBD between 2011 and 2016, with a contemporaneous perioperative
computed tomography (CT) scan, were included. Patient demographics, clinical and biochemical measurements were
collected. Skeletal muscle index and attenuation were measured on perioperative CT scans using Osirix version 5.6.1.
Univariate and multivariate regression analysis was used to identify risk factors for adverse postoperative outcomes.
Results: Seventy-seven patients (46 male, 31 female; mean age 42 years, range 20–80 years) were included. Thirty
patients (30%) had sarcopenia and 26 (34%) had myosteatosis. Myosteatosis was significantly associated with increased
hospital stay postoperatively (9 versus 13 days). Sarcopenia and myosteatosis were associated with hospital readmission
within 30 days on univariate analysis. Multivariate regression analysis demonstrated an independent association
between myosteatosis and hospital readmission. Sixteen patients (21%) had a clinically relevant postoperative
complication, but an association with sarcopenia and myosteatosis was not observed. A neutrophil-lymphocyte ratio
greater than 5 was predictive of clinically relevant postoperative complications on multivariate regression analysis.
Conclusions: Myosteatosis was associated with increased hospital stay and increased 30-day hospital readmission rates
on multivariate regression analysis. Sarcopenia and myosteatosis in IBD were not associated with clinically relevant
postoperative complications.
Keywords: Inflammatory bowel diseases, Sarcopenia, Muscle (skeletal), Morbidity, Length of stay, Tomography (x-ray,
computed)
Key points
 Myosteatosis was associated with increased hospital
stay and increased 30-day hospital readmission rates
for patients who suffer from IBD requiring resection
surgery
 The considerations of sarcopenia and myosteatosis
as potential modifiable risk factors for adverse
postoperative outcomes in patients who suffer
from IBD requiring resection surgery merits
further research
Background
Inflammatory bowel disease (IBD) is a relatively com-
mon chronic inflammatory disorder of the gastrointes-
tinal tract. Ulcerative colitis and Crohn disease are the
principal subtypes. The incidence in Northern Europe is
6.3 per 100,000 person years for Crohn disease and 11.4
for ulcerative colitis [1, 2]. IBD has a complex
pathophysiology consisting of an interaction between
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genetic susceptibility, the environment and the host im-
mune responses.
Clinical differentiation between subtypes is essential
with regard to management decisions. Up to 80% of pa-
tients with Crohn disease will require surgery in their
lifetime and surgery is both an emergency and definitive
therapy for ulcerative colitis [2, 3]. Up to 30% of patients
with ulcerative colitis will require colectomy [2]. These
patients suffer significant nutritional challenges associ-
ated with their pathology as a result of malabsorptive
and chronic inflammatory states.
The incidence of postoperative complications in pa-
tients with IBD undergoing resection surgery ranges
from 20 to 40% [4–6]. Morbidity associated with IBD
may be partly attested to by the characteristics of the
typical preoperative IBD patient: poor nutritional status,
preoperative sepsis (localised or systemic) or intestinal
obstruction. Often these patients will require a number
of investigations in an attempt to delineate disease sever-
ity, disease activity, and the presence of complications in
order to determine optimal management. Computed
tomography (CT) is frequently used for this purpose [7].
CT can also be used to provide additional information
pertaining to patients’ general health, including muscle
volume and attenuation.
Sarcopenia has been defined by the European Working
Group on Sarcopenia in Older People (EWGSOP) as a
low muscle mass and either decreased muscle strength
or low physical performance [8]. Interest in the role of
sarcopenia in surgical patients has grown in the last
number of years, especially in the field of oncology. A
number of recent studies have demonstrated an adverse
association between sarcopenia and immediate and
long-term patient outcomes following surgery including
postoperative complications, length of hospital stay,
recurrence-free, and overall survival [9–11]. Myosteato-
sis is the process of infiltration of lipid into both the in-
ter- and intra-muscular compartments and, similarly to
sarcopenia, has been associated with worse outcomes in
both oncological and non-oncological patients [12, 13].
Previous studies have examined the role of body fat
analysis in association with outcomes of IBD patients
but few studies examining the role of muscle mass and
muscle quality have been conducted [14–16]. The aim of
this study was to investigate sarcopenia and myosteatosis
with respect to postoperative outcomes in patients
undergoing surgical resection for IBD.
Methods
Patients
This study was conducted in accordance with STrength-
ening the Reporting of OBservational studies in Epi-
demiology (STROBE) guidelines [17]. Ethical approval
was granted by the hospital Institutional Research Ethics
Review Board. All consecutive patients who underwent a
colonic resection for IBD, between 2009 and 2016 in a
tertiary referral colorectal surgery service, were retro-
spectively identified from a prospectively maintained
database. Patient medical records were analysed to obtain
baseline demographics, including diagnosis, body mass index
(BMI), presence of comorbidities (scored according to the
American Society of Anesthesiologist [ASA]), preoperative
medications, and smoking status. The Charlson Comorbidity
Index (CCI) [18], which is predictive of 10-year survival and
the neutrophil-lymphocyte ratio (NLR) were calculated for
all patients. Perioperative haematological and biochemical
levels were recorded. All surgeries were carried out by a sin-
gle colorectal surgeon specialised in IBD treatment. The type
of abdominal access and extent of surgical resection were
documented from the operative note. Postoperative compli-
cations were graded according to the Clavien-Dindo classifi-
cation system [19]. Intra-abdominal leaks were classified on
the basis of their management [20]. A leak requiring action
by surgery or interventional radiology was classified as clinic-
ally relevant.
CT protocol, scan selection and image analysis
The hospital information technology system was
searched for perioperative CT of the abdomen and pelvis
in these patients. CT scans within 6 months prior to sur-
gery or in the first postoperative month were selected.
All patients underwent a CT scan of the abdomen and
pelvis with a standardised protocol using the following
parameters: scan range encompassing the lung bases to
the pubic symphysis; 0.625-mm slice acquisition thick-
ness; intravenously administered contrast (Iohexol,
Omnipaque 300, GE Healthcare, Waukesha, WI, USA)
delivered at 2.5 mL/s and imaged in the portal venous
phase; 1.5 L of positive oral contrast (2% Gastrografin,
Bracco Diagnostics Inc., Princeton, NJ, USA); tube volt-
age of 120 kVp; automated tube current modulation
resulting in a variable current with a minimum of
50 mA and a maximum of 350 mA; gantry rotation time
of 0.8 s; noise index 38. All CT images were acquired
using a single 64-slice multi-detector row CT scanner
(General Electric Lightspeed VCT-XTe, GE Healthcare,
GE Medical Systems, Waukesha, WI, USA).
Preoperative scans were preferentially selected. When
these were unavailable, the earliest postoperative scans
were used. The CT scans were analysed using Osirix
version 5.6.1 open source software (32-bit; http://
www.osirix-viewer.com).
The cross-sectional skeletal muscle area (cm3) was
measured, as previously described [11, 21]. Briefly, two
sequential scans at the level of the third lumbar vertebra,
in which both transverse processes were visible, were se-
lected. The grow/regrow tool was used to measure the
skeletal muscle area on these axial slices by a reviewer
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blinded to the patients’ demographics. The skeletal mus-
cles included were the psoas, paraspinal and abdominal
wall muscles. The threshold range for skeletal muscle
was from -30 to +150 Hounsfield Units (HU) [22, 23].
The average muscle mass area of these two slices was
used. The skeletal muscle area was normalised for height
to produce the skeletal muscle index [24]. The specific
cutoff values used for declaring a patient to be affected
with sarcopenia were < 41 cm2/m2 in women, < 43 cm2/
m2 in men with a BMI < 25 kg/m2, and < 53 cm2/m2 in
men with a BMI ≥ 25 kg/m2, as published by Martin et
al. [11]. The cutoff values for myosteatosis were < 41 HU
in men or women with a BMI < 25 kg/m2 and < 33 HU
in men or women with a BMI ≥ 25 kg/m2 [12]. An ex-
ample of the methods employed for image analysis is
demonstrated in Fig. 1.
Statistical analysis
Statistical analysis was carried out using SPSS v20.0 soft-
ware (SPSS Inc., Chicago, IL, USA). Normality was
assessed using the Kolmogorov-Smirnov test. The inde-
pendent t test and Mann-Whitney U test were used to
compare continuous variables. The χ2 and Fischer’s exact
tests were used to compare categorical variables. The
impact of sarcopenia and myosteatosis was analysed by
univariate regression analysis. A p value lower than 0.05
was used as the level of significance.
Results
Ninety-six patients who had had surgery for IBD over
the specified time period were identified from the data-
base but 19 patients were excluded due to the lack of a
suitable CT scan. These 77 patients were included in the
study, 46 of them being male. Patient demographics,
clinical indices, disease location/behaviour and patho-
logical data are summarised in Table 1.
Of the 77 included patients, 30 (39%) were shown to
be affected by sarcopenia and 26 (34%) by myosteatosis.
Of the 52 patients (68%) diagnosed with Crohn disease,
22 had sarcopenia, 30 did not. Of the 21 patients (27%)
diagnosed with ulcerative colitis, 6 had sarcopenia and
15 did not. There were 4/77 patients (5%) with a diagno-
sis of indeterminate colitis, of whom two had sarcopenia
and two did not.
Stratification of patients based on the presence or ab-
sence of sarcopenia demonstrated that only patient
weight and BMI were statistically different between the
groups; patients with sarcopenia had a lower weight and
BMI (p = 0.013 and p = 0.025, respectively). There was
no difference in patient comorbidity profiles, as assessed
by the ASA and CCI scores (p = 0.681 and p = 0.214). Of
the 77 patients, 42 (55%) received preoperative steroid
therapy and 34 patients (44%) had been receiving im-
munosuppressive therapy prior to surgery. While
markers of inflammation, including the mean white cell
count and C- reactive protein, were elevated, there was
no difference between the groups (p = 0.500 and p =
0.252, respectively). Neither was a difference observed in
white cell titres or haemoglobin levels.
Surgical details, including indications for surgery, are
summarised in Table 2. No patients had perianal disease.
Sixty percent of patients had emergency surgery. No dif-
ference was demonstrated between the patients with sar-
copenia and those without in relation to the extent of
surgical resection. Patient outcomes stratified by the
presence of sarcopenia are presented in Table 3.
The median length of hospital stay was 10 days (inter-
quartile range 8–15). There was no significant difference
in median length of hospital admission between patients
with sarcopenia and those without (10 days versus
10 days, p = 0.741). There was a significant difference in
the length of hospital stay between patients with myos-
teatosis and those without (13 days versus 9 days, p =
0.039). Table 4 stratifies the outcomes by the presence of
myosteatosis.
Of 77 patients, 10 (14%) required hospital readmission
within 30 days of surgery. There was a statistically sig-
nificant difference in the number of hospital readmis-
sions between the sarcopenia and the non-sarcopenia
groups (p = 0.030). Patients with myosteatosis also re-
quired readmission more frequently (p = 0.011).
As sarcopenia and myosteatosis were associated with
hospital readmission, we further analysed the strength of
this finding. Univariate and multivariate regression ana-
lysis was used to identify factors associated with hospital
readmissions (Table 4). Sarcopenia and myosteatosis
were significant risk factors for readmission on univari-
ate analysis (odds ratio [OR] = 4.778, p = 0.034 and OR =
6.451, p = 0.012, respectively). Only the presence of
Fig. 1 Example of computed tomography (CT) image analysis methods
on Osirix version 5.6.1 open source software
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Table 1 Clinical indices and pathological data of patients stratified by the presence of preoperative sarcopenia
All patients (n = 77)
n (%)
No sarcopenia (n = 47)
n (%)
Sarcopenia (n = 30)
n (%)
p-value
Age, years (range) 42 (20–80) 41 (21–74) 43(20–80) 0.538a
Gender
Male 46 (60) 31 (66) 15 (50) 0.124b
Female 31 (40) 16 (34) 15 (50)
Diagnosis
Ulcerative colitis 21 (27) 15 (32) 6 (20) 0.504c
Crohn disease 52 (68) 30 (64) 22 (73)
Indeterminate colitis 4 (5) 2 (4) 2 (7)
Location (Crohn)
L1, ileal 14 (27) 9 (30) 5 (23) 0.443
L2, colonic 37 (71) 21 (70) 16 (73)
L3, ileocolonic 1 (2) 0 (0) 1 (4)
Behaviour (Crohn)
B1, non-stricturing, non-penetrating 11 (21) 6 (20) 5 (23) 0.047
B2, stricturing 19 (37) 15 (50) 4 (18)
B3, penetrating 22 (42) 9 (30) 13 (59)
P, perianal disease 0 (0) 0 (0) 0 (0)
Body weight, kg (range) 73 (32–129) 76 (53–118) 70 (32–129) 0.170a
BMI, median (range) 24 (16–37) 24 (19–33) 21 (16–37) 0.037d
BMI categories
Underweight 5 (7) 0 (0) 5 (17) 0.028c
Normal 44 (57) 28 (60) 16 (53)
Overweight 12 (16) 8 (19) 3 (10)
Obese 16 (21) 10 (21) 6 (20)
ASA physical score
Grade 1 13 (17) 9 (19) 4 (13) 0.681c
Grade 2 49 (64) 30 (64) 19 (63)
Grade 3 14 (18) 8 (17) 6 (20)
Grade 4 1 (1) 0 (0) 1 (3)
Charlson Comorbidity Index
0 35 (45) 20 (43) 15 (50) 0.214c
1 20 (26) 15 (32) 5 (17)
2 11 (14) 5 (11) 6 (20)
3 3 (39) 3 (6) 0 (0)
4 2 (26) 0 (0) 2 (7)
5 4 (52) 2 (4) 2 (7)
6 1 (1) 1 (2) 0 (0)
7 1 (1) 1 (2) 0 (0)
Smoking status
Non-smoker 49 (64) 29 (62) 20 (67) 0.558b
Ex-smoker 15 (19) 11 (23) 4 (13)
Smoker 13 (17) 7 (15) 6 (20)
Preoperative steroid therapy
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myosteatosis remained statistically significant on multi-
variate regression analysis (OR = 4.802, p = 0.043)
(Table 5).
Of the 77 patients, 16 (21%) had a Clavien-Dindo
complication score greater or equal to 3a (postoperative
complication treated with intervention not requiring
general anaesthesia), and 11 (14%) had an intra-abdom-
inal leak requiring treatment with surgery or interven-
tional radiology. Univariate and multivariate regression
analysis were used to identify risk factors associated with
significant hospital complications (Clavien-Dindo score ≥
3a) (Table 6). On univariate analysis, age greater than 65
years, CCI ≥ 3 and NLR > 5 were significant risk factors
for complications (OR = 6.444, p = 0.024, OR = 4.167, p
= 0.039 and OR = 4.320, p = 0.021). Only the presence of
a NLR > 5 remained statistically significant on multivari-
ate regression analysis (OR = 4.489, p = 0.024).
Discussion
This study assessed postoperative outcomes, including
length of admission, readmission rates and serious com-
plications, in a cohort of patients with IBD undergoing
resection surgery, stratifying patients based on the pres-
ence of sarcopenia and myosteatosis. The results add to
existing evidence indicating that patients who suffer
from IBD requiring resection surgery who also have
perioperative sarcopenia, and in particular myosteatosis,
require increased postoperative care. The importance of
myosteatosis in relation to postoperative outcomes is
gaining increasing recognition [25] and this study pro-
vides new evidence in this regard.
These findings may form the basis for further assess-
ment of the timing of surgery in such patients, taking
into consideration the influence of pre- and postopera-
tive nutritional status. In fact, many of the surgeries in
IBD patients are performed as emergencies and offer lit-
tle potential to optimise nutritional status prior to sur-
gery. Nevertheless, patients with myosteatosis, despite
spending longer in hospital, were also more likely to re-
quire readmission.
It has been previously demonstrated that hospitalised
patients with IBD have a greater protein-calorie defi-
ciency compared with non-IBD patients [26]. Investiga-
tion of methods for improving the nutritional and
functional status of IBD patients prior to discharge fol-
lowing resection surgery, or also efforts on an outpatient
basis, would help reduce readmission rates. Increased
home visits or earlier review at outpatient clinics could
work in this direction.
Patient selection is a potential confounding factor.
However, the incidence of sarcopenia and postoperative
complications in the present study were within expected
limits. For example, the incidence of sarcopenia in pa-
tients with IBD has been reported to range from 26 to
60% [27–29]. The incidence of sarcopenia in the present
cohort was 39% and, therefore, within this range.
On the other side, patients with ulcerative colitis were
reported to have a lower incidence of sarcopenia
when compared with those with those with Crohn
disease [30], a difference which could potentially
affect outcomes. However, patients with Crohn dis-
ease accounted for the greater proportion of patients
in the present paper.
Table 1 Clinical indices and pathological data of patients stratified by the presence of preoperative sarcopenia (Continued)
All patients (n = 77)
n (%)
No sarcopenia (n = 47)
n (%)
Sarcopenia (n = 30)
n (%)
p-value
No 35 (46) 22 (47) 13 (43) 0.475b
Yes 42 (55) 25 (53) 17 (57)
Preoperative immunosuppression
No 43 (56) 23 (49) 20 (67) 0.098b
Yes 34 (44) 24 (51) 10 (33)
Preoperative anticoagulation
No 73 (95) 45 (96) 28 (93) 0.509c
Yes 4 (5) 2 (4) 2 (7)
Haemoglobin, male (range) 12 (10.5–13.6) 12.6 (10.5–13.7) 11.6 (10.3–12.3) 0.122
Haemoglobin, female (range) 11.6 (10.5–13.6) 12.8 (11.4–13.8) 11.0 (9.8–12) 0.024
White cell count (cells × 109/L) 10.63 (3.7–28.1) 10.88 (5.1–28.1) 10.26 (3.7–19.6) 0.500d
Neutrophil-lymphocyte ratio 7.1 (1.09–26.81) 6.77 (1.09–22.65) 8.02 (1.11–26.81) 0.901d
Albumin (g/L) 34.9 (17–51) 35.28 (20–48) 33.52 (17–51) 0.283d
C-reactive protein (mg/L) 53.04 (0–547) 46.16 (0–374.7) 63.26 (0–547) 0.252d
BMI Body Mass Index, ASA American Society of Anesthesiologists
a Independent t test, b χ2 test, c Fischer’s exact test, d Mann-Whitney U test
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Almost 60% of patients in the present study under-
went emergency surgery, which would have the potential
to increase complication rates. The incidence of postop-
erative complications in the present paper was 21%,
which was also within expected practice as complication
rates of up to 27% have been reported in IBD patients
[6]. A recent study by Pederson et al. [31] reported a
similar incidence of Clavien-Dindo type-3a complica-
tions (25%) and similar length of hospital admission
(8 days) compared with the present study. Six patients
(8%) required reoperation in the present study, which is
again comparable with published data [4, 5, 31].
The present study demonstrated no significant differ-
ence in the incidence of type-3a or greater Clavien-Dindo
Table 2 Operative details stratified by sarcopenia
All patients
(n = 77)
n (%)
No sarcopenia
(n = 47)
n (%)
Sarcopenia
(n = 30)
n (%)
p-value
Elective surgery
Yes 31 (40) 19 (40) 12 (40) 0.581a
No 46 (60) 28 (60) 18 (60)
Indication for surgery
Stage 2 surgery for IPPA 6 (8) 3 (6) 2 (7) 0.850
Stricture 19 (24) 13 (28) 6 (20)
Fistula 9 (12) 6 (13) 4 (13)
Medically refractory disease 33 (43) 18 (38) 15 (50)
Perforation 10 (13) 7 (15) 3 (10)
Type of surgery
Open 18 (23) 7 (15) 11 (37) 0.153b
Laparoscopic 52 (68) 35 (75) 17 (57)
Laparoscopic-assisted 3 (4) 2 (4) 1 (3)
Open→ laparoscopic 4 (5) 3 (6) 1 (3)
Extent of surgery
Completion proctectomy, ileal pouch anal anastomosis and end-ileostomy 5 (7) 3 (6) 2 (7) 0.557b
Panproctocolectomy and end-ileostomy 6 (8) 3 (6) 3 (10)
Sigmoid colectomy 6 (8) 5 (11) 1 (3)
Ileocecectomy 14 (18) 9 (19) 5 (17)
Anastomosis revision 1 (1) 1 (2) 0 (0)
Right hemicolectomy 11 (14) 8 (17) 3 (10)
Subtotal colectomy and end-ileostomy 27 (35) 15 (32) 12 (40)
Left hemicolectomy and defunctioning loop ileostomy 1 (1) 1 (2) 0 (0)
Completion proctectomy and end-ileostomy 3 (4) 1 (2) 2 (7)
Ileorectal anastomosis 2 (3) 0 (0) 2 (7)
Anterior resection and end-colostomy 1 (1) 1 (1) 0 (0)
Elective surgery = planned hospital admission for surgery, non-elective surgery = non-planned surgical intervention. IPPA ileal pouch anal anastomosis
a χ2 test, b Fischer’s exact test
Table 3 Analysis of hospital outcomes by sarcopenia
All patients (n = 77)
n (%)
No sarcopenia (n = 47)
n %
Sarcopenia (n = 30)
n %
p-value
Major complication (Clavien-Dindo ≥ 3a) 16 (21) 10 (21) 6 (20) 0.566a
Major intra-abdominal leak 11 (14) 7 (15) 4 (13) 0.564c
Length of hospital admission (days) median (IQR) 10 (8–15) 10 (8–14) 10.5 (7–18) 0.741b
Hospital readmission < 30 days 10 (14) 3 (6) 7 (23) 0.030c
IQR interquartile range
a χ2 test, b Mann-Whitney U test, c Fischer’s exact test
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complications between sarcopenia and non-sarcopenia pa-
tient groups. Other studies reported differed data in this
regard. Zhang et al. [28] found a decreased incidence of
complications in non-sarcopenia patients (2.3 compared
with 15.7%). However, when comparing this data with our
results, we should consider that the patients were ten years
younger, the definition of sarcopenia was slightly different,
and the prevalence of sarcopenia was more than double.
Patients with IBD are prone to preoperative sarcopenia
and myosteatosis due to a combination of chronic illness,
abdominal pain hindering oral intake, malabsorption and
the effects of medications [32]. In addition, disease ac-
tivity and the pro-inflammatory state of IBD patients
was perioperatively attested to in the present study by
the increased incidence of clinically relevant complica-
tions with a NLR greater than five. This has been noted
previously in the setting of colorectal carcinoma [33].
The treatment of postoperative leaks is very challenging
in IBD patients due to the frequent presence of a hos-
tile abdominal status, resulting in a preference for
non-surgical drainage by interventional radiology ap-
proaches [34].
Table 4 Analysis of hospital outcomes by myosteatosis
All patients (n = 77)
n (%)
No myosteatosis (n = 51)
n (%)
Myosteatosis (n = 26)
n (%)
p-value
Major complication (Clavien-Dindo ≥ 3a) 16 (21) 9 (18) 7 (27) 0.254a
Major intra-abdominal leak 11 (14) 5 (10) 6 (23) 0.111a
Length of hospital admission, days (median, IQR) 10 (8–15) 10 (7–13) 13 (9–24) 0.039b
Hospital readmission < 30 days 10 (13) 3 (6) 7 (27) 0.011c
IQR interquartile range
a χ2 test, b Mann-Whitney U test, c Fischer’s exact test
Table 5 Univariate and multivariate regression analysis for risk factors of readmission
Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age 0.989 0.943–1.037 0.647
Gender (male) 1.462 0.384–5.560 0.578
Diagnosis
Ulcerative colitis 1 1
Crohn 1 0.232–4.310 0.999
Indeterminate colitis 0.00 0.00–infinity 0.000
BMI category
Underweight 1
Normal 0.848 0.082–8.792 0.890
Overweight 0.000 0.00–infinity 0.999
Obese 0.615 0.044–8.703 0.719
ASA physical score ≥ 3 0.000 0.000–infinity 0.999
Charlson Comorbidity Index ≥ 3 0.905 0.099–8.248 0.929
Smoking status
Non-smoker 1
Ex-smoker 2.150 0.448–10.312 0.339
Smoker 1.911 0.319–11.450 0.478
Neutrophil-lymphocyte ratio > 5 1.929 0.496–7.5 0.343
Albumin > 35 g/L 0.606 0.156–2.357 0.606
Preoperative steroid use 3.758 0.740–19.086 0.110
Preoperative immunosuppression 0.756 0.194–2.935 0.686
Emergency surgery 1.703 0.403–7.191 0.469
Sarcopenia 4.778 1.121–20.361 0.034 3.251 0.707–14.951 0.130
Myosteatosis 6.451 1.495–27.829 0.012 4.802 1.053–21.889 0.043
OR odds ratio, CI confidence interval, BMI Body Mass Index, ASA American Society of Anesthesiologists
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The impact of sarcopenia and myosteatosis on postop-
erative outcome has been examined to a greater extent
in patients with colorectal cancer; however, there is a
substantial variability in study methodology and results.
In some reports the presence of sarcopenia and myos-
teatosis failed to show an association with the occur-
rence of intra-abdominal leaks or abscesses in patients
undergoing colorectal cancer surgical resection, which
concurs with the results of the present study [11, 20].
On the other hand, Huang et al. [35] found an association
between sarcopenia and postoperative complications: 10
of 17 patients with sarcopenia had a grade 2 or greater
CCI complication following surgery for colorectal cancer.
This cohort therefore included patients with less complex
complications in comparison with the present study.
The aetiology of sarcopenia and myosteatosis in can-
cer, which contribute to the cancer cachexia state, may
differ from that of a benign condition, such as IBD, in
which the processes causing the altered inflammatory
state are more likely to be reversible either medically by
immunosuppression or by surgical means. In the setting
of cancer, it is generally believed that treating the disease
will reduce the pro-inflammatory drive, but this goal is
often not achievable [36]. Recent papers have reported
that recovery of skeletal muscle volume tends to follow
after induction of infliximab in Crohn disease patients
[37] or after colectomy in ulcerative colitis patients [38].
In the present study, there was no significant difference
in the complication rates between patients with ulcera-
tive colitis and those with Crohn disease.
The classification of patients as affected with sarcope-
nia has been re-examined in recent years. An initial
study by Prado et al. [23] provided cutoff values calcu-
lated in a population of obese patients, which may have
caused skewing of results when applied to the general
population. A follow-up study by Martin et al. [12] pro-
vided updated cutoff values with more heterogeneity in
the cohort. In the present study, no association was
demonstrated between sarcopenia or myosteatosis and
postoperative complications when both the cutoff values
published by Martin et al. or the lowest gender-specific
cutoff were used.
Table 6 Univariate and multivariate regression analysis for risk factors of major complication
Univariate analysis Multivariate analysis
OR 95% CI p-value OR 95% CI p-value
Age > 65 years 6.444 1.274–32.593 0.020 4.274 0.242–75.356 0.321
Gender (male) 0.420 0.122–1.449 0.170
Diagnosis
Ulcerative colitis 1
Crohn 3.167 0.648–15.474 0.154
Indeterminate colitis 3.167 0.215–46.726 0.401
BMI category
Underweight 1 0.631
Normal 0.435 0.063–3.021 0.400
Overweight 0.375 0.035–3.999 0.417
Obese 0.214 0.021–2.187 0.194
ASA physical score ≥ 3 2.318 0.660–8.138 0.189
Charlson Comorbidity index ≥ 3 4.167 1.078–16.103 0.039 1.663 0.141–19.573 0.686
Smoking status
Non-smoker 1 0.228
Ex-smoker 0.684 0.131–3.578 0.653
Smoker 2.778 0.734–10.513 0.132
NLR category > 5 4.320 1.249–14.498 0.021 4.489 1.222–16.494 0.024
Albumin > 35 g/L 0.525 0.169–1.629 0.265
Preoperative steroid use 1.510 0.488–4.676 0.474
Preoperative immunosuppression 0.502 0.156–1.617 0.248
Emergency surgery 2.382 0.690–8.226 0.170
Sarcopenia 0.925 0.297–2.878 0.893
Myosteatosis 1.719 0.557–5.304 0.346
ASA American Society of Anesthesiologists, BMI Body Mass Index, CI confidence interval, NLR neutrophil-lymphocyte ratio, OR odds ratio
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The advent of low-dose CT has assisted in the assess-
ment of acutely unwell patients with IBD who are at in-
creased risk of high cumulative radiation exposure from
diagnostic imaging [39]. This is the first paper to exam-
ine the roles of both sarcopenia and myosteatosis, as
measured by CT, in patients with IBD with respect to
postoperative outcomes. The aetiology of the findings is
less clear due to its retrospective design. The inclusion
of a preoperative quality of life questionnaire and a short
nutritional assessment questionnaire should be consid-
ered in a prospective study. Other methods of investigat-
ing the role of nutritional assessment of patients with
IBD have also been described in the literature. The volu-
metric assessment of visceral fat has been shown to be
associated with postoperative complications and this
could be correlated with CT-derived data [40]. The
addition of preoperative measurements of muscle func-
tion, such as grip strength, could also be considered as
direct comparisons with studies of postoperative out-
comes in older patients with colorectal cancer are likely
to be limited [9, 35].
In conclusion, the present study demonstrated an as-
sociation between myosteatosis and increased hospital
stay in addition to an increased 30-day readmission rate
for patients with IBD undergoing resection. Given the
treatable nature of IBD, there is a potential for sarcope-
nia and myosteatosis to be assessed in terms of poten-
tially modifiable risk factors for adverse postoperative
outcomes and, therefore, for being the target of future
therapeutic targets.
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